» Articles » PMID: 30283902

The Challenges and Opportunities of Pharmacoepidemiology in Bone Diseases

Overview
Journal JBMR Plus
Date 2018 Oct 5
PMID 30283902
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Pharmacoepidemiology is used extensively in osteoporosis research and involves the study of the use and effects of drugs in large numbers of people. Randomized controlled trials are considered the gold standard in assessing treatment efficacy and safety. However, their results can have limited external validity when applied to day-to-day patients. Pharmacoepidemiological studies aim to assess the effect/s of treatments in actual practice conditions, but they are limited by the quality, completeness, and inherent bias due to confounding. Sources of information include prospectively collected (primary) as well as readily available routinely collected (secondary) (eg, electronic medical records, administrative/claims databases) data. Although the former enable the collection of ad hoc measurements, the latter provide a unique opportunity for the study of large representative populations and for the assessment of rare events at relatively low cost. Observational cohort and case-control studies, the most commonly implemented study designs in pharmacoepidemiology, each have their strengths and limitations. However, the choice of the study design depends on the research question that needs to be answered. Despite the many advantages of observational studies, they also have limitations. First, missing data is a common issue in routine data, frequently dealt with using multiple imputation. Second, confounding by indication arises because of the lack of randomization; multivariable regression and more specific techniques such as propensity scores (adjustment, matching, stratification, trimming, or weighting) are used to minimize such biases. In addition, immortal time bias (time period during which a subject is artefactually event-free by study design) and time-varying confounding (patient characteristics changing over time) are other types of biases usually accounted for using time-dependent modeling. Finally, residual "uncontrolled" confounding is difficult to assess, and hence to account for it, sensitivity analyses and specific methods (eg, instrumental variables) should be considered.

Citing Articles

The influence of osteoporosis on mechanical complications in lumbar fusion surgery: a systematic review.

Filley A, Baldwin A, Ben-Natan A, Hansen K, Arora A, Xiao A N Am Spine Soc J. 2024; 18:100327.

PMID: 38962714 PMC: 11219986. DOI: 10.1016/j.xnsj.2024.100327.


Discordance in Published 30-Day Readmission Rates Following Primary Total Hip and Total Knee Arthroplasty: Centers for Medicare and Medicaid Services (CMS) Versus the National Surgical Quality Improvement Program (NSQIP).

Geiger K, Carender C, Feuchtenberger B, Den Hartog T, DeMik D, Elkins J Iowa Orthop J. 2024; 44(1):59-62.

PMID: 38919346 PMC: 11195884.


A Clinical Study of a Standardized Extract of Leaves of (Roxb ex DC) in Postmenopausal Osteoporosis.

Meeta , Raut A, Agashe S, Wajahat A, Sarada C, Vaidya A J Midlife Health. 2019; 10(1):37-42.

PMID: 31001055 PMC: 6459066. DOI: 10.4103/jmh.JMH_22_19.

References
1.
Johannesdottir S, Horvath-Puho E, Ehrenstein V, Schmidt M, Pedersen L, Sorensen H . Existing data sources for clinical epidemiology: The Danish National Database of Reimbursed Prescriptions. Clin Epidemiol. 2012; 4:303-13. PMC: 3508607. DOI: 10.2147/CLEP.S37587. View

2.
Odvina C, Zerwekh J, Rao D, Maalouf N, Gottschalk F, Pak C . Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2004; 90(3):1294-301. DOI: 10.1210/jc.2004-0952. View

3.
Song J, Chung K . Observational studies: cohort and case-control studies. Plast Reconstr Surg. 2010; 126(6):2234-2242. PMC: 2998589. DOI: 10.1097/PRS.0b013e3181f44abc. View

4.
McKee M, Britton A, Black N, McPherson K, Sanderson C, Bain C . Methods in health services research. Interpreting the evidence: choosing between randomised and non-randomised studies. BMJ. 1999; 319(7205):312-5. PMC: 1126943. DOI: 10.1136/bmj.319.7205.312. View

5.
Neviaser A, Lane J, Lenart B, Edobor-Osula F, Lorich D . Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 2008; 22(5):346-50. DOI: 10.1097/BOT.0b013e318172841c. View